• 대한방사성의약품학회지
• /
• 제3권2호
• /
• pp.91-97
• /
• 2017

$^{18}F-THK-5351$ is a PET radiotracer to image the hyperphosphorylated tau fibrillar aggregates in human brain. This protocol describes the optimized radiosynthesis of $^{18}F-THK-5351$ using a commercial GE $TRACERlab^{TM}$ $FX_{FN}$ radiosynthesis module. $^{18}F-THK-5351$ was prepared by nucleophilic [$^{18}F$]fluorination from its protected tosylate precursors, (S)-(2-(2-methylaminopyrid-5-yl)-6-[[2-(tetrahydro-2H-pyran-2-yloxy)-3-tosyloxy]propoxy] quinolone(THK-5352), at $110^{\circ}C$ for 10 min in dimethyl sulfoxide, followed by deprotection with 1 N HCl. The average radiochemical yield of $^{18}F-THK-5351$ was $31.9{\pm}6.7%$(decay-corrected, n = 10), with molar activity of $198.1{\pm}33.9GBq/{\mu}mol$($5.4{\pm}0.9Ci/{\mu}mol$, n = 10). The radiochemical purity was determined to be above 98%. The overall production time including HPLC purification is approximately 70 min. This fully-automated protocol is validated for clinical use.

• 핵의학기술
• /
• 제22권1호
• /
• pp.51-54
• /
• 2018

본 연구는 타우 PET용 방사성의약품으로 개발된 $^{18}F-THK5351$의 임상적용을 위하여 상용화된 자동 합성장치에 적용한 표지방법을 개발하고자 하였다. $^{18}F-THK5351$의 표지법 개발은 HPLC 분리정제 전 표지반응물의 유기용매, 불순물 및 미반응 물질을 제거하기 위해 고체상 추출 카트리지를 사용하여 정제하는 과정을 포함한 방법(method I)과 전처리 정제과정을 포함하지 않은 방법(method II)으로 나누어 진행하였다. $^{18}F-THK5351$ 표지는 $Sep-Pak^{(R)}$ QMA 카트리지를 사용하여 흡착한 불소-18 음이온을 $K_{2.2.2}/K_2CO_3$으로 용출한 후 $100^{\circ}C$에서 진공상태와 헬륨의 흐름하에 건조한 후 표지 전구체와 $110^{\circ}C$에서 10분간 반응시켰다. 반응 후 1 N HCl을 첨가하여 보호기를 제거한 후 0.8 M $CH_3COOK$를 사용하여 표지 반응물을 중화하였다. 이후 전처리 정제의 유무에 따라 method I과 method II로 진행하였다. Method I에서 전처리 정제 과정의 최적화를 위해 $Sep-Pak^{(R)}$ tC18과 $Oasis^{(R)}$ HLB 고체상 추출 카트리지를 사용하여 비교한 결과 $Sep-Pak^{(R)}$ tC18 카트리지는 57.2%의 표지 반응물이 빠져 나갔고, $Oasis^{(R)}$ HLB 카트리지는 40.6%의 표지 반응물이 빠져나가는 것을 확인할 수 있었다. Method I 표지방법의 방사화학적 수율은 $23.8{\pm}1.9%$(decay-corrected, n=4) 이었고, method II 표지방법의 방사화학적 수율은 $31.9{\pm}6.7%$(decay-corrected, n=10) 이었다. 본 연구를 통해 전처리 정제과정을 거쳐 HPLC로 분리정제하는 방법과 전처리 정제과정을 거치지 않고 표지반응물을 바로 HPLC 정제하는 표지방법을 상용화된 자동합성장치를 사용하여 성공적으로 개발하였다. 하지만 전처리 정제과정을 포함한 표지방법은 표지반응물의 손실이 많아 방사화학적 수율이 낮아지는 단점을 발견하였다. 본 연구에서 개발된 전처리 정제과정이 생략된 $^{18}F-THK5351$의 표지방법은 향후 통상적으로 생산 시 보다 유용한 표지방법으로 사용될 것으로 기대된다.

• 대한치매학회지
• /
• 제17권4호
• /
• pp.163-173
• /
• 2018

Background and Purpose: Behavioral variant frontotemporal dementia (bvFTD) is a subtype of frontotemporal dementia, which has clinical symptoms of progressive personality and behavioral changes with deterioration of social cognition and executive functions. The pathology of bvFTD is known to be tauopathy or TDP-43 equally. We analyzed the $^{18}F-THK5351$ positron emission tomography (PET) scans, which were recently developed tau PET, in patients with clinically-diagnosed bvFTD. Methods: Forty-eight participants, including participants with behavioral variant frontotemporal dementia (bvFTD, n=3), Alzheimer's disease (AD, n=21) and normal cognition (NC, n=24) who completed 3T magnetic resonance images, $^{18}F-THK5351$ PET scans, and detailed neuropsychological tests were included in the study. Voxel-wise statistical analysis and region of interest (ROI)-based analyses were performed to evaluate the retention of THK in bvFTD patients. Results: In the voxel-based and ROI-based analyses, patients with bvFTD showed greater THK retention in the prefrontal, medial frontal, orbitofrontal, anterior cingulate, insula, anterior inferior temporal and striatum regions compared to NC participants. Left-right asymmetry was noted in the bvFTD patients. A patient with extrapyramidal symptoms showed much greater THK retention in the brainstem. Conclusions: The distribution of THK retention in the bvFTD patients was mainly in the frontal, insula, anterior temporal, and striatum regions which are known to be the brain regions corresponding to the clinical symptoms of bvFTD. Our study suggests that $^{18}F-THK5351$ PET imaging could be a supportive tool for diagnosis of bvFTD.

• 대한치매학회지
• /
• 제17권3호
• /
• pp.110-119
• /
• 2018

Background and Purpose: To analyze $^{18}F-THK5351$ positron emission tomography (PET) scans of patients with clinically diagnosed nonfluent/agrammatic variant primary progressive aphasia (navPPA). Methods: Thirty-one participants, including those with Alzheimer's disease (AD, n=13), navPPA (n=3), and those with normal control (NC, n=15) who completed 3 Tesla magnetic resonance imaging, $^{18}F-THK5351$ PET scans, and detailed neuropsychological tests, were included. Voxel-based and region of interest (ROI)-based analyses were performed to evaluate retention of $^{18}F-THK5351$ in navPPA patients. Results: In ROI-based analysis, patients with navPPA had higher levels of THK retention in the Broca's area, bilateral inferior frontal lobes, bilateral precentral gyri, and bilateral basal ganglia. Patients with navPPA showed higher levels of THK retention in bilateral frontal lobes (mainly left side) compared than NC in voxel-wise analysis. Conclusions: In our study, THK retention in navPPA patients was mainly distributed at the frontal region which was well correlated with functional-radiological distribution of navPPA. Our results suggest that tau PET imaging could be a supportive tool for diagnosis of navPPA in combination with a clinical history.